Promotion by sodium barbital induces early development but does not increase the multiplicity of hereditary renal tumors in Eker rats.
Induced cell proliferation is important in the mode of action of many non-genotoxic renal carcinogens. Since Tsc2 mutant (Eker) rats are genetically predisposed to the development of renal cell tumors, they provide a useful animal model in which to study the action of renal carcinogens. Sodium barbital was used as a model non-genotoxic renal carcinogen to test whether a concentration that increased renal tubular proliferation without severe nephrotoxicity would enhance tumor induction in a hereditary tumor model. First, a subchronic concentration-response study was conducted in wild-type male Long-Evans rats to determine increased cell proliferation without severe nephrotoxicity. Rats were dosed with sodium barbital in the feed at 0, 50, 250, 500, 1000, 2000 or 4000 p.p.m. for 3 or 8 weeks. Cell proliferation within the cortex and nephrotoxicity were quantitated. Enhanced proliferation with minimal nephrotoxicity occurred at 500 p.p.m. A second study was conducted in male Tsc2 mutant rats given sodium barbital in the feed at 0, 100 or 500 p.p.m. from 9 weeks of age to either 6 or 12 months of age. An additional group of rats was treated with sodium barbital for 6 months and then provided control feed until 12 months of age. Rats necropsied at 6 months of age had a concentration-dependent increase in preneoplastic and total renal lesions. Sodium barbital-treated rats necropsied at 12 months of age had numbers of lesions that were not different from controls. Total combined preneoplastic and neoplastic lesions in the 6 month, high dose group was the same as the 12 month control group. These data show that sodium barbital caused progression to the stage of spontaneous renal lesions in Tsc2 mutant rats but did not increase their overall number. These data suggest that enhanced cell proliferation without significant cytotoxicity exerted a promotional influence in this hereditary model.
Chemical Industry Institute of Toxicology, Research Triangle Park, NC 27709, USA. wolf.doug@epa.gov
D C
DC
Wolf
T L
TL
Goldsworthy
D B
DB
Janszen
R
R
Harden
E M
EM
Donner
C S
CS
David
J I
JI
Everitt
D000818:Animals; D001462:Barbital / Q000633:toxicity*; D002455:Cell Division / Q000187:drug effects; D003043:Cocarcinogenesis; D004305:Dose-Response Relationship, Drug; D020022:Genetic Predisposition to Disease; D006965:Hyperplasia / Q000139:chemically induced / Q000235:genetics; D006993:Hypnotics and Sedatives / Q000633:toxicity*; D007672:Kidney Cortex / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D007680:Kidney Neoplasms / Q000139:chemically induced* / Q000235:genetics*; D007687:Kidney Tubules, Proximal / Q000166:cytology / Q000187:drug effects; D008297:Male; D011230:Precancerous Conditions / Q000139:chemically induced / Q000235:genetics; D051381:Rats; D020318:Rats, Long-Evans
D006993:Hypnotics and Sedatives; D001462:Barbital